Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Cash from Financing Activities (2022 - 2025)

Envoy Medical's Cash from Financing Activities history spans 4 years, with the latest figure at $6.0 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $6.0 million for Q4 2025, up 7.53% from a year ago — trailing twelve months through Dec 2025 was $16.6 million (down 17.65% YoY), and the annual figure for FY2025 was $16.6 million, down 17.65%.
  • Cash from Financing Activities for Q4 2025 was $6.0 million at Envoy Medical, up from $2.6 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $15.7 million in Q3 2023 to a low of -$1.5 million in Q4 2023.
  • The 4-year median for Cash from Financing Activities is $3.8 million (2023), against an average of $4.1 million.
  • The sharpest move saw Cash from Financing Activities crashed 172.7% in 2023, then soared 486.31% in 2024.
  • Year by year, Cash from Financing Activities stood at $2.0 million in 2022, then tumbled by 172.7% to -$1.5 million in 2023, then soared by 486.31% to $5.6 million in 2024, then grew by 7.53% to $6.0 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $6.0 million, $2.6 million, and $4.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.